Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0300 (-2.9%) ($5.0300 - $5.0300) on Fri. Mar. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.15% (three month average) | RSI | 58 | Latest Price | $5.0300(-2.9%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -2.6% a day on average for past five trading days. | Weekly Trend | ADMS advances 1.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TBT(24%) BWX(20%) EMHY(20%) REMX(20%) XLF(19%) | Factors Impacting ADMS price | ADMS will decline at least -2.575% in a week (0% probabilities). BND(-61%) UUP(-32%) TLT(-27%) TAN(-16%) INDA(-16%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.575% (StdDev 5.15%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.15 | 5 Day Moving Average | $5.18(-2.9%) | 10 Day Moving Average | $5.33(-5.63%) | 20 Day Moving Average | $5.15(-2.33%) | To recent high | -24.5% | To recent low | 0.2% | Market Cap | $142m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |